Fu­sion and Cyteir re­fo­cus pipelines; Nona Bio­sciences col­lab­o­rat­ing with Phar­maEssen­tia

Sev­er­al biotechs are look­ing to make changes to their pipelines as the quar­ter has drawn to a close.

Mass­a­chu­setts-based Cyteir said Wednes­day it is go­ing to fo­cus on CYT-0851, which is de­signed to be used in com­bi­na­tion with capecitabine as a treat­ment for ad­vanced ovar­i­an can­cer. For its pre­clin­i­cal DNA poly­merase theta in­hibitor pro­gram, it plans to out-li­cense the pro­gram, the com­pa­ny an­nounced in its Q1 re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER